Seladelpar

• CAT Number: I009423
• CAS Number: 851528-79-5
• Molecular Formula: C21H23F3O5S
• Molecular Weight: 444.465
• Purity: ≥95%
• Target: PPARδ receptor agonist
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid
• InChI: InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
• InChIKey: JWHYSEDOYMYMNM-QGZVFWFLSA-N
• SMILES: CCOC(COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C

Seladelpar (CAT: I009423), also known as MBX-8025 and RWJ-800025, is a selective agonist of the peroxisome proliferator-activated receptor (PPAR)-δ receptor. PPAR-δ is a nuclear receptor involved in the regulation of lipid and glucose metabolism. By activating PPAR-δ, seladelpar may have therapeutic potential in the treatment of various metabolic disorders, including dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). Clinical studies are underway to evaluate the efficacy and safety of seladelpar in these indications.

Reference

1:Choi YJ, Roberts BK, Wang X, Geaney JC, Naim S, Wojnoonski K, Karpf DB, Krauss RM. Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6. doi: 10.1016/j.atherosclerosis.2011.10.029. Epub 2011 Nov 16. PubMed PMID: 22169113.2:Bays HE, Schwartz S, Littlejohn T 3rd, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97. doi: 10.1210/jc.2011-1061. Epub 2011 Jul 13. PubMed PMID: 21752880.